Angina
Findings from D.T. Nash and co-authors provide new insights into angina
Published in Cardiovascular Business Week, November 18th, 2008
"Although the drug's mechanism of action has not been fully elucidated, current thinking is that ranolazine, a selective inhibitor of late sodium influx, attenuates the abnormalities of ventricular repolarisation and contractility associated with ischaemia. Three randomised trials have shown efficacy for ranolazine in increasing exercise testing or reducing anginal episodes or use of glyceryl trinitrate. Side-effects...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Abiomed, Inc.
Sutter Medical Center Honored by Abiomed as "Center of Excellence" for Cardiac Care - ACIST Medical Systems
ACIST Medical Systems Announces Distribution Agreement for StatSensor Creatinine Meter - Akorn, Inc.
Akorn, Inc. Announces FDA Approval of Adenosine Injection USP, 3 mg/mL - American College of Emergency Physicians ACEP
Emergency Physicians Reveal Strategies for Improving Sudden Cardiac Arrest Survival Rates in the U.S. - American Heart Association
Four Medical Centers Awarded Funds to Improve Outcomes Research for Heart Disease and Stroke - Aneurysm
Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
